Peter S. Hendricks - The Consciousness Library

Altered states of leadership: mindfulness meditation, psychedelic use, and leadership development.

Frontiers in Psychology 2023 Otto Simonsson, Cecilia U.D. Stenfors, Simon B. Goldberg et al. 4 citations

Previous research suggests that mindfulness meditation and psychedelic substances show promise as mental health interventions, but relatively little remains known about their potential impact on leadership outcomes. This study aimed to investigate if and how mindfulness meditation and psychedelic use may impact leadership among respondents with a management position as their primary role at...

DOI: 10.3389/fpsyg.2023.1151626 Full text Meditation Psilocybin Psychedelics Leadership-development +4

Prevalence and associations of classic psychedelic-related seizures in a population-based sample.

Drug and Alcohol Dependence October 1, 2022 Otto Simonsson, Simon B. Goldberg, Richard Chambers et al. 16 citations

Previous studies have reported links between classic psychedelic use and seizures, but little remains known about prevalence and potential risk factors of classic psychedelic-related seizures. Using a sample representative of the US adult population with regard to sex, age, and ethnicity (N = 2822), this study examined the prevalence and potential risk factors of classic psychedelic-related...

DOI: 10.1016/j.drugalcdep.2022.109586 Full text LSD Psilocybin Adverse Psychedelics +2

Associations between MDMA/ecstasy use and physical health in a U.S. population-based survey sample

Journal of Psychopharmacology October 1, 2022 Grant Jones, Jocelyn A. Ricard, Peter S. Hendricks et al. 7 citations

INTRODUCTION: 3,4-Methylenedioxymethamphetamine (MDMA/"ecstasy") is an empathogen that can give rise to increased pleasure and empathy and may effectively treat post-traumatic stress disorder. Although prior research has demonstrated associations between ecstasy use and favorable mental health outcomes, the associations between ecstasy and physical health have largely been unexplored. Thus, the...

DOI: 10.1177/02698811221127318 Ecstasy Odds ratio Population Body mass index +3

Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling

Neuropharmacology August 17, 2022 Jack E Henningfield, Marion A Coe, Roland R. Griffiths et al. 34 citations

New medicines containing classic hallucinogenic and entactogenic psychedelic substance are under development for various psychiatric and neurological disorders. Many of these, including psilocybin, lysergic acid diethylamide (LSD), and 3,4-methylenedioxymethamphetamine (MDMA) are Schedule I controlled substances of the United States Controlled Substances Act (US CSA), and similarly controlled...

DOI: 10.1016/j.neuropharm.2022.109220 Clinical study design Consciousness Controlled substance regulation Drug scheduling +9

Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations

Neuropharmacology May 13, 2022 Cynthia E. Ortiz, Haley Maria Dourron, Noah W Sweat et al. 26 citations

Psilocybin-facilitated psychotherapy shows potential transdiagnostic efficacy for a range of mental health conditions. Though vulnerable populations bear disproportionate mental health burden, they have been largely neglected in the clinical psilocybin literature. However, if the field is to best respond to the diverse needs of individuals from vulnerable populations, care must be taken to...

DOI: 10.1016/j.neuropharm.2022.109127 Psilocybin Mental health Context archaeology Alliance +5

Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study

Journal of Psychopharmacology March 1, 2022 Neiloufar Family, Peter S. Hendricks, Luke T. J. Williams et al. 23 citations

Background: Classic psychedelics hold promise as therapeutics for psychiatric disorders, but require scalable intervention protocols. This proof-of-concept study evaluated the safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg lysergic acid diethylamide (LSD) in healthy adults within a novel intervention paradigm. Methods: Up to three participants were...

DOI: 10.1177/02698811211069103 Tolerability Pharmacokinetics Intervention counseling Proof of concept +3

Perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide in healthy participants within a novel intervention paradigm: Qualitative results from a proof-of-concept study

Journal of Psychopharmacology March 1, 2022 Peter S. Hendricks, Heith Copes, Neiloufar Family et al. 8 citations

Background: Classic psychedelics show promise in the treatment of mental health conditions; however, more scalable intervention protocols are needed to maximize access to these novel therapeutics. In this proof-of-concept study, perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide (LSD) were evaluated among healthy participants ( N =...

DOI: 10.1177/02698811211055855 Lysergic acid diethylamide Thematic analysis Intervention counseling Qualitative research +4

Classic psychedelics, health behavior, and physical health.

Therapeutic Advances in Psychopharmacology 2022 Otto Simonsson, Peter S. Hendricks, Richard Chambers et al. 26 citations

Preliminary evidence suggests that classic psychedelics may be effective in the treatment of some psychiatric disorders, yet little remains known about their effects on health behavior and physical health. The purpose of this study was to investigate associations of lifetime classic psychedelic use and psychological insight during one's most insightful classic psychedelic experience with health...

DOI: 10.1177/20451253221135363 Full text Psilocybin Magic mushrooms Bmi Behavior +7

Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs.

The International journal on drug policy December 1, 2021 David B. Yaden, Andrea P Berghella, Paul S. Regier et al.

Several pilot studies have provided evidence supporting the potential of classic psychedelics like psilocybin in the treatment of substance use disorders (SUDs). If larger trials confirm efficacy, classic psychedelic-assisted psychotherapy may eventually be integrated into existing addiction treatments such as cognitive behavioral therapy, contingency management, and medication-assisted...

DOI: 10.1016/j.drugpo.2021.103380 Full text Community Harm reduction Psychedelics Twelve step

Associations between lifetime classic psychedelic use and cardiometabolic diseases

Scientific Reports July 13, 2021 Otto Simonsson, Walter Osika, Robin Carhart-Harris et al. 54 citations

Abstract The objective of the current study was to investigate the associations between lifetime classic psychedelic use and cardiometabolic diseases. Using data from the National Survey on Drug Use and Health (2005–2014), the present study examined the associations between lifetime classic psychedelic use and two types of cardiometabolic disease: heart disease and diabetes. Respondents who...

DOI: 10.1038/s41598-021-93787-4 Full text Odds ratio Disease Diabetes mellitus Cardiovascular health +2

Associations between lifetime classic psychedelic use and markers of physical health

Journal of Psychopharmacology March 9, 2021 Otto Simonsson, James D. Sexton, Peter S. Hendricks 75 citations

BACKGROUND: In recent years, there has been significant research on the mental health effects of classic psychedelic use, but there is very little evidence on how classic psychedelics might influence physical health. AIMS: The purpose of the present study was to investigate the associations between lifetime classic psychedelic use and markers of physical health. METHODS: Using data from the...

DOI: 10.1177/0269881121996863 Overweight Body mass index Odds ratio Mental health +4

Association Between Lifetime Classic Psychedelic Use and Hypertension in the Past Year

Hypertension March 8, 2021 Otto Simonsson, Peter S. Hendricks, Robin Carhart-Harris et al. 36 citations

Using data from the National Survey on Drug Use and Health (2005–2014), weighted to be representative of the US adult population, the present study investigated the association between lifetime classic psychedelic use and hypertension in the past year among adults in the United States. The results showed that respondents who reported having used a classic psychedelic at least once in their...

DOI: 10.1161/hypertensionaha.120.16715 Association psychology

Psilocybin-assisted group therapy: A new hope for demoralization

EClinicalMedicine October 1, 2020 Peter S. Hendricks 5 citations

Anderson et al.’s [[1]Anderson B.T. Danforth A. Daroff R. Stauffer C. Ekman E. Agin-Liebes G. et al.Psilocybin-facilitated group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study.Eclinical Med. 2020; https://doi.org/10.1016/j.eclinm.2020.100538Summary Full Text Full Text PDF Scopus (74) Google Scholar] open-label pilot study of...

DOI: 10.1016/j.eclinm.2020.100557

Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics

Frontiers in Psychiatry February 11, 2020 James D. Sexton, Charles D. Nichols, Peter S. Hendricks 45 citations

IntroductionThe majority of contemporary psychedelic research has focused on ayahuasca, lysergic acid diethylamide, and psilocybin, though there are hundreds of novel psychedelic compounds that may have clinical utility. The purpose of the present study was to evaluate the therapeutic potential of classic and novel phenethylamine, tryptamine, and lysergamide psychedelics via a large, nationally...

DOI: 10.3389/fpsyt.2019.00896 Full text Psychedelic-assisted therapy Psychedelic therapy Phenethylamines Tryptamines +16

Prevalence and epidemiological associates of novel psychedelic use in the United States adult population.

Journal of psychopharmacology (Oxford, England) September 1, 2019 James D. Sexton, Michael S Crawford, Noah W Sweat et al. 33 citations

Novel psychedelics approximate classic psychedelics, but unlike classic psychedelics, novel psychedelics have been used by humans for a shorter period of time, with fewer data available on these substances. The purpose of this study was to determine the prevalence of novel psychedelic use and the associations of novel psychedelic use with mental health outcomes. We estimated the prevalence of...

DOI: 10.1177/0269881119827796 Full text Hallucinogen Mental health Phenethylamines Novel psychedelic use +1

Accounting for Microdosing Classic Psychedelics

Journal of Drug Issues August 30, 2019 Blake Beaton, Heith Copes, Megan Webb et al. 13 citations

Microdosing classic psychedelics (e.g., LSD [lysergic acid diethylamide] and psilocybin) is the practice of taking small amounts of these substances to bring about various positive life changes. Little is known about the subjective experiences and perceptions of those who engage in the practice. Accordingly, we use the sociology of accounts as a theoretical framework to explore the ways that...

DOI: 10.1177/0022042619871008 Appeal Denial Microdose

Narrative identity, rationality, and microdosing classic psychedelics

International Journal of Drug Policy May 8, 2019 Megan Webb, Heith Copes, Peter S. Hendricks 75 citations

BackgroundMicrodosing involves ingesting a small dose of a classic psychedelic (e.g., LSD and psilocybin) at regular intervals for prolonged periods. The practice is said to reduce anxiety, improve mood, and offer several creative and practical benefits to users. Using the narrative identity theoretical framework, our aim was to explore the experiences of those who microdosed classic...

DOI: 10.1016/j.drugpo.2019.04.013

Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.

Pharmacology & Therapeutics May 1, 2019 Matthew W Johnson, Peter S. Hendricks, Frederick S. Barrett et al. 520 citations

The purpose of this paper is to provide an integrative review and offer novel insights regarding human research with classic psychedelics (classic hallucinogens), which are serotonin 2A receptor (5-HT2AR) agonists such as lysergic acid diethylamide (LSD), mescaline, and psilocybin. Classic psychedelics have been administered as sacraments since ancient times. They were of prominent interest...

DOI: 10.1016/j.pharmthera.2018.11.010 Full text Addiction Depression LSD Psilocybin +6

Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy

International Review of Psychiatry July 4, 2018 Peter S. Hendricks 181 citations

A psychological model of classic psychedelic-assisted psychotherapy informed by contemporary scientific data is presented in this paper. It is suggested that classic psychedelic-occasioned mystical experience is characterized by profound awe, a discrete emotion experienced in the presence of a vast stimulus requiring accommodation of mental structures. Awe, in turn, promotes the small self, a...

DOI: 10.1080/09540261.2018.1474185

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act

Neuropharmacology June 5, 2018 Matthew W. Johnson, Roland R. Griffiths, Peter S. Hendricks et al. 348 citations

This review assesses the abuse potential of medically-administered psilocybin, following the structure of the 8 factors of the US Controlled Substances Act (CSA). Research suggests the potential safety and efficacy of psilocybin in treating cancer-related psychiatric distress and substance use disorders, setting the occasion for this review. A more extensive assessment of abuse potential...

DOI: 10.1016/j.neuropharm.2018.05.012 Psilocybin Hallucinogen Substance abuse Pharmacology

The relationships of classic psychedelic use with criminal behavior in the United States adult population

Journal of Psychopharmacology October 17, 2017 Peter S. Hendricks, Michael S Crawford, Karen L. Cropsey et al. 91 citations

Criminal behavior exacts a large toll on society and is resistant to intervention. Some evidence suggests classic psychedelics may inhibit criminal behavior, but the extent of these effects has not been comprehensively explored. In this study, we tested the relationships of classic psychedelic use and psilocybin use per se with criminal behavior among over 480,000 United States adult...

DOI: 10.1177/0269881117735685 Psilocybin Hallucinogen Criminal behavior Population +4

The Associations of Naturalistic Classic Psychedelic Use, Mystical Experience, and Creative Problem Solving

Journal of Psychoactive Drugs October 8, 2016 Noah W Sweat, Larry W. Bates, Peter S. Hendricks 48 citations

Developing methods for improving creativity is of broad interest. Classic psychedelics may enhance creativity; however, the underlying mechanisms of action are unknown. This study was designed to assess whether a relationship exists between naturalistic classic psychedelic use and heightened creative problem-solving ability and if so, whether this is mediated by lifetime mystical experience....

DOI: 10.1080/02791072.2016.1234090 Mysticism Creativity Task project management Naturalism +6

Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use

Journal of Psychopharmacology April 19, 2016 Zach Walsh, Peter S. Hendricks, Stephanie D. Smith et al. 63 citations

Evidence suggests that hallucinogens may have therapeutic potential for addressing a variety of problem behaviors related to the externalizing spectrum of psychopathology, such as substance misuse and criminality. Intimate partner violence (IPV) is a prevalent form of criminal violence that is related to externalizing pathology. However, the association between hallucinogen use and IPV has not...

DOI: 10.1177/0269881116642538 Hallucinogen Poison control Psychopathology Injury prevention +4

Psilocybin, psychological distress, and suicidality

Journal of Psychopharmacology September 1, 2015 Peter S. Hendricks, Matthew W Johnson, Roland R. Griffiths 107 citations

Hendricks et al. (2015) found that having ever used any classic psychedelic substance—namely, dimethyltryptamine (DMT), ayahuasca, lysergic acid diethylamide (LSD), mescaline, peyote or San Pedro, or psilocybin—was associated with a significantly reduced likelihood of past month psychological distress (weighted OR = .81 (.72–.91)), past year suicidal thinking (weighted OR = .86 (.78–.94)), past...

DOI: 10.1177/0269881115598338 Full text Psilocybin Psychological distress Hallucinogen Clinical psychology +1

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population.

Journal of psychopharmacology (Oxford, England) March 1, 2015 Peter S. Hendricks, Christopher B Thorne, C Brendan Clark et al. 377 citations

Mental health problems are endemic across the globe, and suicide, a strong corollary of poor mental health, is a leading cause of death. Classic psychedelic use may occasion lasting improvements in mental health, but the effects of classic psychedelic use on suicidality are unknown. We evaluated the relationships of classic psychedelic use with psychological distress and suicidality among over...

DOI: 10.1177/0269881114565653 Full text Lysergic acid diethylamide Psilocybin Psychedelic Hallucinogen +3

Papers